Invero Pharma is a partnership between Invero Health LLC and JMB Capital Partners Lending LLC. We are a late clinical-stage pharmaceutical and medical device company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury. Invero Pharma is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA) following a publication of positive Phase II Clinical Trial results in JAMA.¹
Invero Pharma believes xenon holds great promise due to its multiple mechanisms of action, extensive pre-clinical results² and positive Phase II clinical trial results which demonstrated a reduction in brain tissue damage and directionally better survival outcomes. Invero Pharma intends to become a leader in the development and commercialization of drug/device neuroprotective products that help prevent brain damage and improve mortality rates in patient populations experiencing acute injury to the brain.
For inquiries and information on how to join us in our mission, please contact us here.
¹ Laitio et. al. ,JAMA. 2016;315(11):1120-1128. doi:10.1001/jama.2016.1933
² Maze, Can J Anesth/J Can Anesth. DOI 10.1007/s12630-015-0507-8
INVERO PHARMA LEADERSHIP
Douglas Stefanelli – President and CEO
With over 40 years in the Pharmaceutical Industry Doug brings extensive expertise in both commercial and clinical development from his time at Berlex Laboratories, Bayer Healthcare and Averitas Pharma. Specializing in creating new markets, leading large teams, developing major brands and creating unique business solutions. He led the Berlex Laboratories Specialized Therapeutics responsible for the Neurology and Cardiology franchises, and while at Bayer was General Manager responsible for managing the US Hospital Business, successfully launching and promoting unique procedure based products in hospitals and diagnostic facilities. He co-founded Averitas Pharma, ran the company as President, gained FDA approval for a new indication in a billion dollar market and successfully sold the assets to Gruenenthal GmbH.
His experience in drug/equipment development and deep understanding of the sales and marketing models within hospital systems is invaluable to Invero Pharma’s development and commercialization of Xenex.
Kenneth Liss – CCO
With more than 40 years’ experience in pharmaceuticals, holding many critical positions at Berlex Laboratories, Bayer Healthcare and Averitas Pharma, including VP Sales and Chief Commercial Officer, Ken brings significant commercial and business knowledge to the organization. He is an Industry recognized healthcare executive specializing in customer centric solutions. While at Berlex and Bayer, Ken managed the largest franchises, Neurology and Women’s Healthcare, as VP Sales, achieving the highest revenue figures for two major brands. He co-founded Averitas, managed the entire commercial operations and successfully sold the assets to Gruenenthal GmbH.
He brings an extensive experience managing and integrating commercial teams as well as a significant background in discovering and rebranding undervalued assets.
Robert Milos – CBO
Bob has over 45 years of experience in US pharmaceuticals including Warner Lambert, CR Bard, Cooper Laboratories, Schering AG (Berlex), Bayer Healthcare and Averitas Pharma. He has designed and implemented cost accounting and IT systems, was the CFO for US based operations, headed US business development activities as Schering AG transformed itself into a pure pharmaceutical company by acquiring two biotech companies and spinning off four chemical business subsidiaries, reorganized US human resource infrastructure and policies, and was VP and GM for the Hospital Products Division for nine years. Before coming to Invero, Bob was the Co-founder and COO of Averitas, creating a US operational setup that was successfully sold to Gruenenthal GmbH.
Bob brings to Invero a significant history and expertise in prosperous deal-making and operational know-how. His deep industry knowledge, from discovery to commercialization, is a tremendous asset to Invero.
Matt Napoletano – COO
Matt is an accomplished pharmaceutical executive bringing more than 30 years of industry experience. Prior to joining Invero he served as COO of Neuroprotexeon (former owner of the Xenex technology). As COO he successfully raised over $20 million to support the clinical and technical development of Xenex. He managed and led the teams at NPXe to see the product enter Phase III before Invero acquired the technology.
Matt worked in positions of increasing importance at Insys Therapeutics, Cephalon Inc. (Teva Pharmaceutical), and Berlex Laboratories (Bayer). He played a lead role in the commercialization of multiple products and line extensions in the areas of supportive care, pain management, women’s health, diagnostic imaging and radiopharmaceuticals, as well as the clinical development of Xenon gas for inhalation.
Matt brings a significant understanding and knowledge of all aspects of the Xenex technology. His prior work at NPXe has given Invero vital enrichment in moving this technology back into clinical research, and soon-to-be, clinical use.